Table 6.
Identification of the hub genes related to the survival of GBM patients.
| Upregulated Hub Genes | Survival Rate (in Months) | Log-Rank p | p(HR) | Downregulated Hub Genes | Survival Rate (in Months) | Log-Rank p | p (HR) |
|---|---|---|---|---|---|---|---|
| IL6 | 49 | 0.07 | 0.074 | PCNA | 52 | 0.87 | 0.85 |
| VEGFA | 49 | 0.05 | 0.046 | POLR2H | 52 | 0.46 | 0.47 |
| SRC | 52 | 0.24 | 0.25 | RPS3 | 52 | 0.07 | 0.077 |
| CXCL8 | 49 | 0.04 | 0.05 | UBA52 | 52 | 0.14 | 0.15 |
| IDH1 | 49 | 0.03 | 0.029 | CCNB1 | 71 | 0.7 | 0.72 |
| PTGS2 | 52 | 0.54 | 0.54 | UBE2C | 71 | 0.77 | 0.79 |
| EGFR | 49 | 0.93 | 0.9 | ||||
| APP | 71 | 0.46 | 0.47 | ||||
| ALDOA | 71 | 0.11 | 0.11 | ||||
| SQSTM1 | 71 | 0.13 | 0.13 |
Analysis was done using the Gene Expression Profiling Interactive Analysis (GEPIA) online tool, and the relationship between the hub gene expression and its significance in resistance was verified using the method of Kaplan–Meier for the survival analysis, as described in detail in the legend to Figure 6. The survival rate, log-rank p, and hazard ratio (HR) of the hub genes were extracted from Figure 6 and presented. p and p(HR) ≤ 0.05 were considered significant.